IL22 and colitis: While exogenous administration of IL-22 ameliorates﻿ this phenotype, transferring the microbiome of IL-22 or IL-23 pathway-deficient animals to wild-type mice leads to reduced AMP and IL-22 expression in the gut and, again, increased sensitivity to chemically induced colitis [9, 12, 13].